ClinicalTrials.gg
CompletedNCT03067909Updated Feb 8, 2019

Antithrombotic Therapy in Patients Undergoing CIED Surgery - HEMATOMA NO MORE Registry

An observational study in Device Related Infection, Antithrombotic Drugs and Cardiac Arrhythmia, sponsored by Azienda Ospedaliera Universitaria Senese. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-08.

Sponsored by Azienda Ospedaliera Universitaria Senese · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,450
Ages
18 Years and older
Sex
All
01

Study summary

Hundreds of thousands patients undergo implantation or replacement of cardiac implantable electronic devices (CIEDs) annually in Europe, and up to 50% of these subjects receive antiplatelet agents or oral anticoagulants. Antithrombotic therapy increases the risk of developing pocket hematoma which in turn is associated with an increased risk of potentially fatal device-related infections when clinically significant. Aim of the registry is to retrospectively (pilot local registry in Tuscany) and prospectively (multicenter national registry in Italy) investigate the different strategies for the management of antithrombotic therapy and the related complication rates (1-month and 12-months) in patients undergoing CIED surgery in a real-world setting. The registry will also provide data on the economic impact of different management strategies and complications.

02

Conditions studied

  • Device Related Infection
  • Antithrombotic Drugs
  • Cardiac Arrhythmia
  • Surgery--Complications
  • Hematoma
03

In context

Prosthesis-Related Infections

35 studies on the registry are indexed under Prosthesis-Related Infections; 10 are open to participants now.

This study's enrollment of 1,450 is above the median of 60 across 15 observational studies indexed under Prosthesis-Related Infections.

Browse Prosthesis-Related Infections studies →

Lead sponsor

Azienda Ospedaliera Universitaria Senese is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients taking antithrombotic therapy undergoing CIED surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with standard indications to CIED surgery being treated with antiplatelet agents and/or anticoagulants (any commercially available device or approved and marketed drug can be included).
  • Patients able to provide written
  • Patients willing to attend the planned follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Patient with less than 12 months as per investigator's judgement
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,450 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Patients undergoing CIED surgery

    Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).

    Other: CIED surgery

Interventions

  • OtherCIED surgery
06

What researchers measure

Primary outcomes

  1. Clinically significant pocket hematoma

    Post-procedural hematoma resulting in prolonged hospitalization and/or requiring interruption of antithrombotic therapy and/or requiring further surgery and/or requiring transfusion

    Time frame: One month

Secondary outcomes

  1. Non-clinically significant pocket hematoma

    Post-procedural hematoma not meeting diagnostic criteria for clinically significant

    Time frame: One month

  2. Hemorrhagic complications other than pocket hematoma

    Hemothorax, cardiac tamponade, pericardial effusion, intracranial hemorrhage

    Time frame: One month

  3. Thromboembolic complications

    Transient ischemic attack, ischemic stroke, deep venous thrombosis, pulmonary embolism, systemic embolic event, acute myocardial infarction, prosthetic cardiac valve thrombosis

    Time frame: Twelve months

  4. All cause death

    Time frame: Twelve months

  5. CIED-related infection

    Time frame: Twelve months

07

Study locations

1 site
  • AOU Senese
    Siena, 53100, Italy
08

References and documents

Publications

  • Zaca V, Breschi M, Mandorli A, Panchetti L, Ricciardi G, Viani S, Notarstefano P. Rationale, study design, and pilot phase of tHE Management of AntiThrOMbotic therApy (HEMATOMA) in patients undergoing electrophysiological device surgery: Italian National Multicenter Observational REgistry. J Cardiovasc Med (Hagerstown). 2017 Nov;18(11):897-899. doi: 10.2459/JCM.0000000000000534. PubMed 28594654 ↗
  • V Zaca', A Angeletti, C Baiocchi, M Bertini, M Biffi, P Busacca, M Iori, M Mezzetti, M Nesti, P Notarstefano; P3213 Real-world periprocedural management of antithrombotic therapy in patients undergoing electrophysiological device surgery: preliminary results of the HEMATOMA NO MORE, European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy563.P3213, https://doi.org/10.1093/eurheartj/ehy563.P3213

Individual participant data

Plan to share: Yes — IPD will be made available on demand to other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Sep 2017, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2017
First posted
Mar 1, 2017
StartActual
May 2016
Primary completionActual
Sep 2017
CompletionActual
Dec 2018
Last update
Feb 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03067909
Lead sponsor
Azienda Ospedaliera Universitaria Senese
Responsible party
Valerio Zacà (Principal Investigator, Cardiology Consultant, Arrhythmology Unit, Cardiothoracic and Vascular Department, Azienda Ospedaliera Universitaria Senese) — Principal investigator
First posted
Mar 1, 2017
Start date
May 2016
Primary completion
Sep 2017
Completion
Dec 2018
Last update
Feb 8, 2019

Study contacts

Valerio Zacà, MD
principal investigator · AOU Senese

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion